AB-MK-002

N/A

Report date: 2025/03/18 16:38:21

Base Information

Drug NameAB-MK-002

Drug Alias NameAB-MK-002

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cell replacementsImmunologic cytotoxicity

TargetsUpdating

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesArtiva Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesArtiva Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A